| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8430dfed10baf5168628141d8c8d4f09 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-718
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575 |
| filingDate |
2005-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d32661fc57748df4dcbb8c747c3c1579 |
| publicationDate |
2010-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2255812-A1 |
| titleOfInvention |
Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| abstract |
A composition comprising a clear aqueous solution comprising: n(a) a first material selected from soluble ursodeoxycholic acid or a sodium salt oftauroursodeoxycholic acid (TUDCA); n(b) a carbohydrate selected from the group consisting of an aqueous soluble starch conversion product or an aqueous soluble non-starch polysaccharide; n(c) water, wherein the first material and the carbohydrate both remain in solution for any subset of the range of pH values obtainable in an aqueous system sufficient for a pharmaceutical formulation to remain in solution from preparation, to administration, to absorption in the body; n nfor use in the treatment of at least one symptom of a neurodegenerative disease or at least one symptom of a motor neuron disease in a subject. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11071742-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021126320-A1 |
| priorityDate |
2004-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |